To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.
The Accelerating Medicines Partnership–Schizophrenia is the first neuropsychiatric project of the landmark Accelerating Medicines Partnership program managed by the Foundation for the National Institutes of Health.
The NiP- Metastatic Prostate Cancer Project will re-examine the Cou302 database to further optimize the radiographic progression-free survival (rPFS) endpoint to include additional factors that may influence overall survival. The model in development will be a first-in-prostate cancer predictive model to incorporate imaging
The Neuroscience Steering Committee, led by the FNIH and its co-chairs Dr. Linda Brady, Dr. Hartmuth Kolb, and the emeritus co-chair Dr. Bill Potter, is bringing together experts in the field of neuroscience from industry, NIH, FDA, and academia to present progress to date, next steps, and key obstacles that need to be addressed in order to drive biomarker development in a multitude of neuroscience focus areas.
The National Institutes of Health (NIH)’s Fogarty International Center celebrated its 50th anniversary of accomplishments and hosted a Scientific Symposium on May 1st, 2018 at the Natcher Auditorium on NIH’s campus. The program convened a series of panel discussions with NIH leaders, Fogarty grantees, and key stakeholders, to identify key gaps in global health research and strategize future research initiatives.
As part of a larger national effort to address the opioid crisis, the FNIH is leading the planning effort for a potential public-private scientific partnership that includes the NIH, FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and more than 30 biopharmaceutical companies.
The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $220 million launched by the National Institutes of Health, the FNIH and 12 leading pharmaceutical companies as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the FNIH.
The National Institute of Nursing Research hosted a two-day Summit to gather a variety of stakeholder perspectives on the spectrum of caregiving issues and research for conditions and illnesses that may occur across the lifespan.
Under Dr. Charles A. Sanders’ visionary leadership, the FNIH has influenced the course of biology and medicine over the past 20 years. At the Charles A. Sanders, M.D., Scientific Symposium, hear from scientific leaders, including Lurie Prize in Biomedical Sciences awardees, to learn more about the latest pioneering biomedical research.
Plasticity and Mechanisms of Cognitive Remediation in Older Adults supports a grant for a multicenter clinical research trial on remediating age-related cognitive decline through mindfulness-based stress reduction and exercise.
The Cancer Research Fund enables individuals to support cancer research at the National Cancer Institute (NCI).